Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin immunotherapy

Ultrastructural Pathology

Volumn 36, Issue 5, 2012, Pages 320-324

  Ajili, Faouzia ^a,b   Manai, Mohamed ^b   Darouiche, Amine ^c   Chebil, Mohamed ^c   Boubaker, Samir ^a  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

^b FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^c CHARLES NICOLLE HOSPITAL   (Tunisia)

Author keywords

BCG immunotherapy; Bladder cancer; Prognostic; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLADDER TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOLOGY; INTRAVESICAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MULTIPLE CANCER; MULTIVARIATE ANALYSIS; PATHOLOGY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCG VACCINE; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

MYCOBACTERIUM BOVIS BCG;

EID: 84866948280     PISSN: 01913123     EISSN: 15210758     Source Type: Journal    
DOI: 10.3109/01913123.2012.681833     Document Type: Article

References (30)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 2001;51:15-36.
2. Sellami A, Jlidi R, Hsairi M, Achour N. Registre du cancer du sud Tunisie 1997. Hôpital Habib Bourguiba. 2000;2:32-35.
3. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF. Superficial bladder cancer treated with Bacillus Calmette-Guérin: a multivariate analysis of factors affecting tumor progression. J Urol. 1989;141: 22-29. (Pubitemid 19028816)
4. Herr HW, Schwalb DM, Zhang ZF, et al. Intravesical BCG therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995;13:1404-1408.
5. Saint F, Salomon L, Quintela R. Do prognostic parameters of remission versus relapse after bacillus Calmette-Guérin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol. 2003;43:351-361. (Pubitemid 36427453)
6. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 2001; 166:1296-1299. (Pubitemid 32862159)
7. Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49: 466-477.
8. Takashi M, Wakai K, Hattori T, et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ. Int Urol Nephrol. 2002;33:41-47. (Pubitemid 34575409)
9. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163:73-78.
10. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22:1435-1448. (Pubitemid 28550639)
11. Sobin DH, Wittekind CH, eds. TNM Classification of Malignant Tumours, 6th ed. New York: Wiley-Liss; 2002: 199-202.
12. Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette-Guérin of existing papillary bladder cancer and carcinoma in situ of the bladder: four-year results. Cancer. 1995;75:552-559.
13. Cookson MS, Sarosdy MF. Management of stage T1 superficial bladder cancer with intravesical Bacillus Calmette- Guerin therapy. J Urol. 1992;148:797-801.
14. Martinez-Pineiro JA, Flores N, Isorna S, et al. Long-term follow-up of randomised prospective trial comparing a standard 81 mg dose of intravesical Bacillus Calmette-Guérin with reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002;89:671-680. (Pubitemid 34429530)
15. Zlotta RA, Noel JC, Fayt I, et al. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki67 expression in patients with superficial bladder tumors treated with Bacillus Calmette-Guérin intravesical therapy. J Urol. 1999;161:792-798. (Pubitemid 29422368)
16. Davis JW, Sheth SI, Doviak MJ, Schellhammer PF. Superficial bladder carcinoma treated with Bacillus Calmette-Guerin: progression-free and disease specific survival with 10-year minimum followup. J Urol. 2002;167:494-501.
17. Kondylis FI, Demirci S, Ladaga L, Kolm P, Schellhammer PF. Outcomes after intravesical Bacillus Calmette-Guérin are not affected by substaging of high grade T1 transitional cell carcinoma. J Urol. 2000; 163:1120-1123. (Pubitemid 30169375)
18. van der Meijden AP, Sylvester RJ. BCG immunotherapy for superficial bladder cancer: an overview of the past, the present and the future. EAU Update Series. 2003;1:80-86 (Pubitemid 40411076)
19. Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guérin: 18-year experience. Urology. 2002; 59:227-231. (Pubitemid 34134520)
20. Lebret T, Bohin D, Kassardjian Z, et al. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose Bacillus Calmette-Guérin instillations. J Urol. 2000;163:63-67.
21. Yuge K, Kikuchi E, Matsumoto K, Takeda T, Miyajima A, Oya M. Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy? Jpn J Clin Oncol 2011;41(4):565-570.
22. Saint F, Salomon L, Quintela R. Do prognostic parameters of remission versus relapse after bacillus Calmette-Guérin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol. 2003;43:351-361. (Pubitemid 36427453)
23. Takashi M, Wakai K, Hattori T, et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ. Int Urol Nephrol. 2002;33:41-47. (Pubitemid 34575409)
24. Martinez-Pineiro JA, Flores N, Isorna S, et al., for CUETO (Club Urologico Espanol de Tratamiento Oncologico). Longterm follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacilli Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002;89:671-680. (Pubitemid 34429530)
25. Shinka T, Matsumoto M, Ogura H, Hirano A, Ohkawa T. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: a long-term follow-up. Int J Urol. 1997;4: 139-143. (Pubitemid 27182653)
26. Joudi FN, Smith BJ, O'Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006;175:1634-1639.
27. Cho KS, Hwang TK, Kim BW, et al, for the Korean Urological Oncology Society. Differences in tumor characteristics and prognosis in newly diagnosed Ta, T1 urothelial carcinoma of bladder according to patient age. Urology. 2009:73:828-832.
28. Losa A, Hurle R, Lembo A. Low dose Bacillus Calmette-Guérin for carcinoma in situ of the bladder: long-term results. J Urol. 2000; 163:68-72.
29. Boorjian SA, Zhu F, Herr HW. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int. 2010;106(3):357-361.
30. Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008;53: 992-1002. (Pubitemid 351434495)